C型肝炎の世界市場レポート 2025年

C型肝炎の市場規模は、今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）15.1％で1,340億3,000万米ドルに成長します。予測期間の成長は、世界の撲滅活動、検査とスクリーニングの改善、ヘルスケア支出の増加、遠隔医療の統合、新たな治療法の組み合わせなどに起因すると考えられます。予測期間における主な動向には、アクセスしやすく手頃な治療費、ハイリスクグループへの注力、薬剤製剤の改良、共同研究やパートナーシップ、遠隔医療、デジタルソリューションなどがあります。

ウイルス感染症の増加が今後のC型肝炎市場の成長を牽引すると予測されます。ウイルス感染症とは、体内のウイルスによって引き起こされる感染症のことです。C型肝炎の治療は、ウイルスを除去し、ウイルス除去後の罹患患者の免疫反応を回復させることで、ウイルス感染を抑えることができます。例えば、2024年8月、米国の公衆衛生機関である疾病対策予防センター（CDC）は、季節性呼吸器ウイルス感染症であるパルボウイルスB19に罹患している人の割合がすべての年齢層で上昇し、2022年から2024年にかけての3％から2024年6月には10％に増加したと報告しました。最も顕著な増加は5～9歳の小児で、2022～2024年の15％から2024年6月には40％に急増しました。さらに、パルボウイルスB19のDNA濃度を示すプール検体の割合は、2023年12月の1.5％から2024年6月には19.9％へと大幅に増加しました。このように、ウイルス感染症の増加がC型肝炎市場の成長に寄与しています。

肝炎の有病率の増加は、今後のC型肝炎市場の成長を後押しすると予想されます。肝炎は肝臓の炎症症状であり、ウイルス感染、特にA、B、C、D、Eなどの肝炎ウイルスによって引き起こされることが多いです。高リスク集団に焦点を当て、患者擁護団体からの支援を受けながら、C型肝炎市場は進歩を続け、この感染症を管理する革新的なソリューションと進歩を提供しています。例えば、2024年4月にCDCは、非ヒスパニック系黒人の急性B型肝炎罹患率が11.1％増加し、2021～2022年の間に非ヒスパニック系白人の1.7倍となったと報告しました。したがって、肝炎の有病率の上昇がC型肝炎市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界C型肝炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のC型肝炎市場：成長率分析
• 世界のC型肝炎市場の実績：規模と成長, 2019-2024
• 世界のC型肝炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界C型肝炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のC型肝炎市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性C型肝炎
• 急性C型肝炎
• その他のタイプ
• 世界のC型肝炎市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗ウイルス薬
• ワクチン
• 免疫調節薬
• 手術
• その他の治療
• 世界のC型肝炎市場：診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肝生検
• 血液検査
• 画像検査
• その他の診断
• 世界のC型肝炎市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院および薬局
• オンライン薬局
• 世界のC型肝炎市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 外来手術センター
• 診断検査室
• 調査機関
• 在宅ケア設定
• 世界のC型肝炎市場、タイプ別サブセグメンテーション：慢性C型肝炎のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子1型
• 遺伝子2型
• 遺伝子3型
• 遺伝子4型
• 遺伝子5型
• 遺伝子6型
• 世界のC型肝炎市場、タイプ別サブセグメンテーション：急性C型肝炎のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 症状あり
• 無症状
• 世界のC型肝炎市場、タイプ別サブセグメンテーション：その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 混合感染
• 重複感染

第7章 地域別・国別分析

• 世界のC型肝炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のC型肝炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• C型肝炎市場：競合情勢
• C型肝炎市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffman La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• Sumitomo Corporation
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH.
• Amgen Inc.
• Toray Industries Inc.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Otsuka Pharmaceutical Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• C型肝炎市場2029：新たな機会を提供する国
• C型肝炎市場2029：新たな機会を提供するセグメント
• C型肝炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hepatitis C is a viral infection that mainly targets the liver, causing inflammation, liver damage, and potentially leading to cirrhosis or liver cancer if left untreated. The virus spreads through contact with infected blood and is treated with antiviral medications designed to eliminate the virus from the bloodstream.

The main types of hepatitis C are chronic hepatitis C, acute hepatitis C, and others. Chronic hepatitis C denotes a persistent infection caused by the hepatitis C virus, occurring when the body is unable to effectively combat the virus. Treatment options for chronic hepatitis C include antiviral drugs, vaccines, immune modulator drugs, surgery, and others. The diagnostic process typically involves liver biopsy, blood tests, imaging tests, and others, with distribution through hospital and retail pharmacies, as well as online pharmacies. End-users encompass hospitals, clinics, ambulatory surgical centers, diagnostic laboratories, research institutes, and home care settings.

The hepatitis C market research report is one of a series of new reports from The Business Research Company that provides hepatitis C market statistics, including hepatitis C industry global market size, regional shares, competitors with a hepatitis C market share, detailed hepatitis C market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatitis C industry. This hepatitis C market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis C market size has grown rapidly in recent years. It will grow from $67.17 billion in 2024 to $76.32 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to blood transfusion practices, injection drug use, limited treatment options, development of direct-acting antivirals (DaaS)

The hepatitis C market size is expected to see rapid growth in the next few years. It will grow to $134.03 billion in 2029 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to global elimination efforts, improved testing and screening, rising healthcare spending, integration of telemedicine, emerging therapeutic combinations. Major trends in the forecast period include accessible and affordable treatment, focus on high-risk groups, improved drug formulations, collaborative efforts and partnerships, telehealth and digital solutions.

An increase in viral infections is anticipated to drive the growth of the hepatitis C market in the future. Viral infections refer to those caused by viruses in the body. Treatment for hepatitis C helps reduce viral infection by eliminating the virus and restoring the immune response in affected patients after viral clearance. For example, in August 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, reported that the percentage of individuals with Parvovirus B19, a seasonal respiratory viral infection, rose across all age groups, increasing from 3% during 2022-2024 to 10% in June 2024. The most notable rise was among children aged 5-9 years, where prevalence surged from 15% during 2022-2024 to 40% by June 2024. Additionally, the proportion of pooled samples showing parvovirus B19 DNA levels significantly increased from 1.5% in December 2023 to 19.9% in June 2024. Thus, the rise in viral infections is contributing to the growth of the hepatitis C market.

The increasing prevalence of hepatitis is expected to boost the growth of the hepatitis C market in the future. Hepatitis is an inflammatory condition of the liver, often caused by viral infections, particularly hepatitis viruses like A, B, C, D, and E. With a focus on high-risk populations and support from patient advocacy groups, the hepatitis C market continues to progress, providing innovative solutions and advancements in managing this infectious disease. For instance, in April 2024, the CDC reported that the rate of acute hepatitis B among non-Hispanic Black individuals increased by 11.1%, resulting in a rate 1.7 times higher than that of non-Hispanic White individuals during 2021-2022. Therefore, the rising prevalence of hepatitis is driving the hepatitis C market.

A noteworthy trend gaining popularity in the hepatitis C market is the advancement in diagnostic technologies. Major companies in the market are adopting new technologies to maintain their market positions. In July 2022, F. Hoffmann-La Roche Ltd. introduced the Elecsys HCV Duo immunoassay, allowing the independent and simultaneous determination of hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample. The test aids in identifying patients recovering from or exhibiting symptoms of chronic infection, potentially leading to other diseases such as liver cancer.

Key players in the hepatitis C market are concentrating on developing advanced products, including dual antigen and antibody diagnostic tests, to enhance the accuracy and efficiency of early detection and treatment. A dual antigen and antibody diagnostic test identifies both the presence of hepatitis C virus (HCV) antigens and antibodies in a patient's blood. For example, in July 2023, Roche Diagnostics, a Switzerland-based company specializing in diagnostic tests, instruments, and digital solutions, launched the Elecsys HCV Duo in India. This dual antigen and antibody diagnostic test is designed for the simultaneous detection of both HCV antigen and antibodies from a single plasma or serum sample. The dual detection feature addresses the challenge posed by asymptomatic early infections, which frequently go undiagnosed due to the lack of antibodies in the initial stages. By enabling the identification of active infections at an earlier stage, the Elecsys HCV Duo assists healthcare providers in initiating appropriate treatment plans more swiftly, potentially mitigating disease progression and reducing transmission rates.

In September 2022, Gilead Sciences Inc. partnered with Brigham and Women's Hospital, Harvard Medical School, and Beth Israel Deaconess Medical Center for Health Advancement in Vietnam (HAIVN). This public-private initiative aims to improve the management of viral hepatitis in Vietnam and the Philippines, aligning with the global goal of hepatitis C elimination by 2030. The collaboration involves institutions such as Brigham and Women's Hospital and Beth Israel Deaconess Medical Center in the U.S. and Harvard Medical School.

Major companies operating in the hepatitis C market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffman La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sumitomo Corporation, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH., Amgen Inc., Toray Industries Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Lupin Limited, Cadila Healthcare Ltd., Biocon Limited

North America was the largest region in the hepatitis C market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis c market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hepatitis c market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The hepatitis C market consists of revenues earned by entities by providing shunt procedures, hepatic resection, and biopsies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis C market also includes sales of ledipasvir and sofosbuvir, non-structural protein 5B (NS5B) polymerase inhibitors, non-structural protein 5A (NS5A) replication complex inhibitors, and elbasvir and grazoprevir drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis C Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis c market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis c ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatitis c market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Chronic Hepatitis C; Acute Hepatitis C; Other Types
• 2) By Treatment: Antiviral Drugs; Vaccine; Immune Modulator Drugs; Surgery; Other Treatments
• 3) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
• 4) By Distribution Channel: Hospital And Retail Pharmacies; Online Pharmacies
• 5) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Diagnostic Laboratories; Research Institutes; Home Care Settings
• Subsegments:
• 1) By Chronic Hepatitis C: Genotype 1; Genotype 2; Genotype 3; Genotype 4; Genotype 5; Genotype 6
• 2) By Acute Hepatitis C: Symptomatic; Asymptomatic
• 3) By Other Types: Mixed Infections; Superinfection
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffman La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hepatitis C Market Characteristics

3. Hepatitis C Market Trends And Strategies

4. Hepatitis C Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Hepatitis C Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hepatitis C PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hepatitis C Market Growth Rate Analysis
• 5.4. Global Hepatitis C Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hepatitis C Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hepatitis C Total Addressable Market (TAM)

6. Hepatitis C Market Segmentation

• 6.1. Global Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Hepatitis C
• Acute Hepatitis C
• Other Types
• 6.2. Global Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiviral Drugs
• Vaccine
• Immune Modulator Drugs
• Surgery
• Other Treatments
• 6.3. Global Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liver Biopsy
• Blood Tests
• Imaging Tests
• Other Diagnosis
• 6.4. Global Hepatitis C Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital And Retail Pharmacies
• Online Pharmacies
• 6.5. Global Hepatitis C Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Research Institutes
• Home Care Settings
• 6.6. Global Hepatitis C Market, Sub-Segmentation Of Chronic Hepatitis C, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genotype 1
• Genotype 2
• Genotype 3
• Genotype 4
• Genotype 5
• Genotype 6
• 6.7. Global Hepatitis C Market, Sub-Segmentation Of Acute Hepatitis C, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Symptomatic
• Asymptomatic
• 6.8. Global Hepatitis C Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mixed Infections
• Superinfection

7. Hepatitis C Market Regional And Country Analysis

• 7.1. Global Hepatitis C Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hepatitis C Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatitis C Market

• 8.1. Asia-Pacific Hepatitis C Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatitis C Market

• 9.1. China Hepatitis C Market Overview
• 9.2. China Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatitis C Market

• 10.1. India Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatitis C Market

• 11.1. Japan Hepatitis C Market Overview
• 11.2. Japan Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatitis C Market

• 12.1. Australia Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatitis C Market

• 13.1. Indonesia Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatitis C Market

• 14.1. South Korea Hepatitis C Market Overview
• 14.2. South Korea Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatitis C Market

• 15.1. Western Europe Hepatitis C Market Overview
• 15.2. Western Europe Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatitis C Market

• 16.1. UK Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatitis C Market

• 17.1. Germany Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatitis C Market

• 18.1. France Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatitis C Market

• 19.1. Italy Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatitis C Market

• 20.1. Spain Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatitis C Market

• 21.1. Eastern Europe Hepatitis C Market Overview
• 21.2. Eastern Europe Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatitis C Market

• 22.1. Russia Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatitis C Market

• 23.1. North America Hepatitis C Market Overview
• 23.2. North America Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatitis C Market

• 24.1. USA Hepatitis C Market Overview
• 24.2. USA Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatitis C Market

• 25.1. Canada Hepatitis C Market Overview
• 25.2. Canada Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatitis C Market

• 26.1. South America Hepatitis C Market Overview
• 26.2. South America Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatitis C Market

• 27.1. Brazil Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatitis C Market

• 28.1. Middle East Hepatitis C Market Overview
• 28.2. Middle East Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatitis C Market

• 29.1. Africa Hepatitis C Market Overview
• 29.2. Africa Hepatitis C Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hepatitis C Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hepatitis C Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatitis C Market Competitive Landscape And Company Profiles

• 30.1. Hepatitis C Market Competitive Landscape
• 30.2. Hepatitis C Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffman La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hepatitis C Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Bristol-Myers Squibb Company
• 31.4. Sumitomo Corporation
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Boehringer Ingelheim International GmbH.
• 31.9. Amgen Inc.
• 31.10. Toray Industries Inc.
• 31.11. Mylan N.V.
• 31.12. Teva Pharmaceutical Industries Ltd.
• 31.13. Daiichi Sankyo Company Limited
• 31.14. Eisai Co. Ltd.
• 31.15. Otsuka Pharmaceutical Co. Ltd.

32. Global Hepatitis C Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatitis C Market

34. Recent Developments In The Hepatitis C Market

35. Hepatitis C Market High Potential Countries, Segments and Strategies

• 35.1 Hepatitis C Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hepatitis C Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hepatitis C Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer